Simon Xi, Rgenta Therapeutics CEO
Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca
Cambridge, MA biotech Rgenta Therapeutics has secured $52 million in a Series A to take oral small molecules into the clinic.
The 20-person biotech, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
